Ipamorelin: FDA status, evidence and safety

Status at a glance

What ipamorelin is

Ipamorelin is a synthetic growth hormone secretagogue, a compound that prompts the pituitary to release growth hormone. WADA lists it in the same class as lenomorelin (ghrelin), ibutamoren (MK-677) and macimorelin. It is marketed for body composition, recovery and sleep, often combined with CJC-1295.

Human evidence

The human research FDA highlights is a safety signal, not a benefit: “A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility” (FDA). We did not find controlled trials showing benefit for the body-composition or anti-ageing uses clinics advertise, and we have not re-read the literature for this update, so we cite no efficacy trial.

Animal and laboratory evidence

The case for ipamorelin as a selective growth-hormone releaser rests largely on early pharmacology and animal studies. That is a mechanism, not an outcome in people.

Risks

FDA keeps ipamorelin in 503B Category 2 because it has identified significant safety risks with its use in compounding. The serious adverse events FDA cites came from intravenous use in a clinical setting; the risks of self-injected products from unregulated sellers are less studied and harder to trace.

Legal sourcing: who can supply it

For 503A pharmacies, ipamorelin has no approval, bulks-list entry or category as of October 15, 2026. For 503B outsourcing facilities, Category 2 signals that FDA does not extend its usual enforcement discretion. Either way, there is no established lawful compounding route. See peptide legality and CJC-1295 / ipamorelin.

The lawful route for a prescription peptide in the United States is a licensed clinician who examines you and writes a prescription, filled by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility that is allowed to use that substance. Websites that sell peptides “for research use only” or “not for human consumption” are not a lawful source of medicine for people. On August 24, 2026, FDA sent warning letters to five such sellers — Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and Tex Peptides — calling their products unapproved new drugs. FDA wrote that the research-use labels did not change its view because the websites showed the products were meant for human use.

October 2026: what changed

• April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
• July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
• October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.

For ipamorelin: the 503B Category 2 listing did not change in April, and ipamorelin was not on the July PCAC agenda. FDA’s August letters show it is enforcing against blends that pair ipamorelin with tesamorelin. Whether the interim policy covers ipamorelin is unknown.